A 92.9% objective response rate in second-line CLL patients who progressed on a BTK inhibitor but never received a BCL2 inhibitor is an attention-grabbing number from an early-cohort dataset, but the more durable signal in bexobrutideg’s updated Phase 1a/b readout is the 22.1-month median progression-free survival in heavily pretreated patients carrying a median of four prior lines of therapy. That cohort included patients with BTK resistance mutations, TP53 alterations, and CNS involvement, populations that routinely underperform on existing oral BTK inhibitors. Sustaining responses through those features is where a degrader’s mechanism, eliminating the protein rather than just occupying its active site, earns its clinical argument.
The Phase 1b expansion data, though still early, sharpens the strategic picture. In Cohort 5, 18 of 19 BTKi-experienced, BCL2i-naïve patients remained on treatment at the January 2026 cutoff after a median follow-up of just 5.2 months. Cohort 15, enrolling BTKi-naïve and treatment-naïve patients, returned an 84.2% ORR with 19 of 20 patients still on therapy. These numbers cannot be read as mature efficacy yet, but they reframe bexobrutideg as a candidate across all treatment lines rather than a salvage option. That repositioning directly supports the broad Phase 3 monotherapy program Nurix is advancing and makes the Roche collaboration, which spans malignant hematology, immunology, and neurology, look less like an opportunistic licensing deal and more like a calculated bet on a full-line asset. The tolerability profile across 142 patients, with treatment discontinuations due to adverse events in only 5.6% and no dose-limiting toxicities, removes one of the most common early-phase reasons for pivotal programs to stall.
The competitive context matters here. Ibrutinib and second-generation covalent inhibitors like acalabrutinib and zanubrutinib are deeply entrenched across CLL lines, and venetoclax has reset expectations for time-limited combination therapy. Bexobrutideg has to demonstrate it does something categorically different, not merely equivalent, in patients who have already failed the agents that define the current standard. The CNS penetrance and activity in mutation-driven resistant disease are the features that credibly answer that question today.
The single marker to track from the EHA presentation is the progression-free survival curve in the BTK-resistance mutation subgroup within Cohort 5. If durability in that population holds through longer follow-up, it is the clearest justification for a pivotal program and the strongest differentiator against covalent BTK inhibitors that lose ground exactly where bexobrutideg claims to gain it.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
